• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

    11/14/24 9:53:10 AM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email
    SC 13G/A 1 fp0091019-1_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 2)

     

    Champions Oncology, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    15870P307

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ]Rule 13d-1(b)
    [X]Rule 13d-1(c)
    [  ]Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages) 

     

     

    CUSIP NO. 15870P307

    13G Page 2 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    WEST ELK PARTNERS, LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    STATE OF DELAWARE, UNITED STATES OF AMERICA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    N/A

     
    6

    SHARED VOTING POWER

     

    882,581 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

     

    N/A

     
    8

    SHARED DISPOSITIVE POWER

     

    882,581 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    882,581 shares of Common Stock

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.49% of the outstanding shares of Common Stock

     
    12

    TYPE OF REPORTING PERSON

     

    PN (Limited Partnership)

     

     

     

    CUSIP NO. 15870P307

    13G Page 3 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    WEST ELK, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    STATE OF DELAWARE, UNITED STATES OF AMERICA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    N/A

     
    6

    SHARED VOTING POWER

     

    882,581 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

     

    N/A

     
    8

    SHARED DISPOSITIVE POWER

     

    882,581 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    882,581 shares of Common Stock

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.49% of the outstanding shares of Common Stock

     
    12

    TYPE OF REPORTING PERSON

     

    OO (Limited Liability Company)

     

     

     

    CUSIP NO. 15870P307

    13G Page 4 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    WEST ELK CAPITAL, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    STATE OF DELAWARE, UNITED STATES OF AMERICA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    N/A

     
    6

    SHARED VOTING POWER

     

    882,581 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

     

    N/A

     
    8

    SHARED DISPOSITIVE POWER

     

    882,581 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    882,581 shares of Common Stock

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.49% of the outstanding shares of Common Stock

     
    12

    TYPE OF REPORTING PERSON

     

    OO (Limited Liability Company), IA (Investment Adviser)

     

     

     

    CUSIP NO. 15870P307

    13G Page 5 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Jason Joffe

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    UNITED STATES OF AMERICA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    N/A

     
    6

    SHARED VOTING POWER

     

    882,581 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

     

    N/A

     
    8

    SHARED DISPOSITIVE POWER

     

    882,581 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    882,581 shares of Common Stock

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.49% of the outstanding Common Stock

     
    12

    TYPE OF REPORTING PERSON

     

    IN (Individual)

     

     

     

    CUSIP NO. 15870P307

    13G Page 6 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Morgan Duke

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    UNITED STATES OF AMERICA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    N/A

     
    6

    SHARED VOTING POWER

     

    882,581 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

     

    N/A

     
    8

    SHARED DISPOSITIVE POWER

     

    882,581 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    882,581 shares of Common Stock

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.49% of the outstanding Common Stock

     
    12

    TYPE OF REPORTING PERSON

     

    IN (Individual)

     

     

     

    Item 1.(a) Name of Issuer:

     

    Champions Oncology, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    One University Plaza

    Suite 307

    Hackensack, New Jersey 07601

     

    Item 2.(a) Name of Persons Filing:

     

    West Elk Partners, LP

    West Elk, LLC

    West Elk Capital, LLC

    Jason Joffe

    Morgan Duke

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    For all persons filing:

     

    1175 Peachtree Street NE

    Suite 360

    Atlanta, GA 30361

     

    (c)Citizenship:

     

    West Elk Partners, LP is a Delaware limited partnership

    West Elk, LLC is a Delaware limited liability company

    West Elk Capital, LLC is a Delaware limited liability company

    Mr. Joffe and Mr. Duke are United States citizens

     

    (d)Title of Class of Securities:

     

    Common Stock

     

    (e)CUSIP Number:

     

    15870P307

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable. Filed pursuant to Rule 13d-1(c). 

     

     

    Item 4.Ownership.

     

       

    West Elk

    Partners, LP

    West Elk,

    LLC

    West Elk

    Capital, LLC

    Jason Joffe

    Morgan

    Duke

    (a) Amount Beneficially Owned: 882,581 882,581 882,581 882,581 882,581
    (b) Percent of Class: 6.49% 6.49% 6.49% 6.49% 6.49%
    (c) Number of Shares to Which Reporting Person Has:          
      (i) Sole Voting Power: N/A N/A N/A N/A N/A
      (ii) Shared Voting Power: 882,581 882,581 882,581 882,581 882,581
      (iii) Sole Dispositive Power: N/A N/A N/A N/A N/A
      (iv) Shared Dispositive Power: 882,581 882,581 882,581 882,581 882,581

     

    The reported shares are the Issuer’s common stock.

     

    All of the reported shares are owned directly by West Elk Partners, LP (“West Elk Partners”), whose general partner is West Elk, LLC (the “General Partner”) and whose investment adviser is West Elk Capital, LLC (the “Investment Adviser”). The General Partner and the Investment Adviser could each be deemed to be indirect beneficial owners of the reported shares, and could be deemed to share such beneficial ownership with West Elk Partners.

     

    Jason Joffe and Morgan Duke are the managers of the General Partner and Investment Adviser, and could be deemed to share such indirect beneficial ownership with the General Partner, the Investment Adviser, and West Elk Partners.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable. 

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below, each of the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    Signature

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

      Date: November 14, 2024  

     

     

    WEST ELK PARTNERS, LP

     
           
      By:

    West Elk, LLC, General Partner

     
           
      By:

    /s/ Jason Joffe

     
      Name:

    Jason Joffe

     
      Title:

    Manager

     
           
      Date: November 14, 2024  

     

     

    WEST ELK, LLC

     
           
      By:

    /s/ Jason Joffe

     
      Name:

    Jason Joffe

     
      Title:

    Manager

     
           
      Date: November 14, 2024  

     

     

    WEST ELK CAPITAL, LLC

     
           
      By:

    /s/ Jason Joffe

     
      Name:

    Jason Joffe

     
      Title:

    Manager

     
           
      Date: November 14, 2024  

     

      /s/ Jason Joffe  
      Jason Joffe  

     

      Date: November 14, 2024  

     

      /s/ Morgan Duke  
      Morgan Duke  

     

    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces the Addition of Brady Davis as President

      HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

      10/17/23 8:30:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces Addition to Board of Directors

      HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

      2/22/21 9:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/16/24 11:45:44 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/12/24 12:47:07 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/11/24 10:57:35 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

      SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      11/14/24 9:53:10 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

      SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      5/6/24 7:46:06 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Champions Oncology Inc.

      SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      2/12/24 9:12:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/17/25 11:03:52 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/11/25 4:32:41 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      12/16/24 4:16:03 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Champions Oncology upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

      9/12/24 9:23:16 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roth Capital reiterated coverage on Champions Oncology with a new price target

      Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

      3/15/21 10:03:32 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Financials

    Live finance-specific insights

    See more
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

      HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

      9/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      4/2/25 4:20:36 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Breitfeld Philip P.

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 12:14:09 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sidransky David

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 11:47:41 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care